| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192312 | Annals of Allergy, Asthma & Immunology | 2010 | 8 Pages |
Abstract
The 1.5% bepotastine besilate formulation produced statistically significant reductions after a CAC in individual nonocular symptoms and NOCS scores at onset of allergic response and for at least 8 hours after instillation, with the greatest reduction seen for nasal congestion and rhinorrhea.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Gail L. MD, Jon I. PhD, James A. MD, Paul J. MS, Mark B. MD, Timothy R. PharmD, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group Bepotastine Besilate Ophthalmic Solutions Clinical Study Group,